Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets
about
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMCOptimal Use of Vaccines for Control of Influenza A Virus in SwineDeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadMolecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza virusesExpression and Characterization of Recombinant, Tetrameric and Enzymatically Active Influenza Neuraminidase for the Setup of an Enzyme-Linked Lectin-Based AssayModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesInfluenza virus neuraminidase (NA): a target for antivirals and vaccines.Influenza vaccines: a moving interdisciplinary field.Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategiesBacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferretsA novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodiesA rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cellsH5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.Towards universal influenza vaccines?Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferretsA VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virusProtective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice.A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates.In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines.Biological and protective properties of immune sera directed to the influenza virus neuraminidase.Morphology of influenza B/Lee/40 determined by cryo-electron microscopyBinding of avian coronavirus spike proteins to host factors reflects virus tropism and pathogenicity.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSVEvasion of influenza A viruses from innate and adaptive immune responses.Identification of Residues That Affect Oligomerization and/or Enzymatic Activity of Influenza Virus H5N1 Neuraminidase Proteins.Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.Immunosilencing a highly immunogenic protein trimerization domain.Adaptation of novel H7N9 influenza A virus to human receptors.Kinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses.Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
P2860
Q24329089-E0F4DDC2-80B1-4C31-BE7B-2177DD4CD2DAQ26783503-F7D0E555-196D-41F2-A0B6-2CAC36FBA9EAQ26783897-C2B1CF6B-CE3A-4522-982B-D7F5FB8E094DQ28387782-4E21D590-A208-4343-8D05-DBC287703EF8Q28547305-0C5DFE19-268C-43A4-8B5E-B5CAD0CBD262Q30209342-66AA5D78-3CB1-4ABE-B0A5-794CCD4DF60CQ30249879-F7A7FB52-7BEB-4BE0-8C36-3A9F22F93358Q30367695-3FC82751-5505-4ED0-BCE2-300469DA0CB7Q30373917-66FD3A0B-A6EC-40E6-8202-C3C730CA6A50Q30374446-D3C89050-D0F3-4884-ABB7-F860AE153DACQ30386612-E41DE293-09F6-43EE-A9A8-B65E48C97840Q30386823-1D775D16-70C3-43A9-8FDF-42A6391E5B8BQ30396343-50967C3B-7869-4FF8-ACC4-2122DB5CCD58Q30398277-6F74F16D-6B3F-40D0-AD02-C6B50691A4F8Q30398811-C89CAA99-DC34-47D8-B58D-D7B3E9DD15B6Q30400550-E4FF2789-BB78-4FA6-96B0-5067188F29F9Q30406365-F1CB0583-1443-4C23-AF5B-0CB3CFBD35B8Q30406748-0797A641-667F-43D2-875A-40EFDE509C4AQ30407657-DB36BD59-109F-44FD-A59A-922D1E825F6AQ30413023-D6A0EE3B-8121-4F54-B3F4-FE938B679EAFQ30420210-1CFA660D-B9B9-4EA2-8F16-14EF99F130B9Q30421007-F2382989-D623-4A54-84FB-55AB5D7E8EBBQ30431659-9F11193A-2233-4531-B732-D8F24BC851CDQ33820732-408C3348-E3BC-4F33-8F16-5B90CB4C8180Q33927420-39037150-934B-4D90-AE85-69FCB50D3C94Q34991399-22F6FC85-82D0-40C6-9CBA-38BCFF7A9D15Q35091674-E117B47F-D9A7-4DB5-82F4-516086D5BCE4Q35192873-9029A873-B400-45D6-BAC4-202DA5E846B3Q35826733-7F6C6DE6-B7A2-4048-B819-1C3734153E58Q36075789-A9D1540D-53D6-4002-9A2F-8202BBD51E7AQ36363190-57CCE2BA-8379-4BE2-A2E9-37152BC73B7AQ36408162-E7D8CFD1-8B83-46AF-8889-0A702AD8805AQ37002523-F84DEB0D-E54C-45B8-8814-DAD269D07B9AQ38061423-C4B9DA63-E994-4234-85B2-3904913EBC5CQ38752513-4C3EF2C3-17EA-4E33-A7FD-9121F3C333B8Q38852557-54BDEEBC-BD15-4771-9DA5-0B55F5AE367EQ41506957-F248A376-5FE4-4F8A-99B3-2E23B9262A1EQ41816698-2E193C72-7DF7-4C42-B11A-C9A980DF1775Q41918783-FA05EE02-0976-4454-86ED-108F8DB842DEQ41933365-9BBC2041-5753-467F-A7EE-962F9FB6D033
P2860
Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Recombinant soluble, multimeri ...... nza virus infection in ferrets
@ast
Recombinant soluble, multimeri ...... nza virus infection in ferrets
@en
type
label
Recombinant soluble, multimeri ...... nza virus infection in ferrets
@ast
Recombinant soluble, multimeri ...... nza virus infection in ferrets
@en
prefLabel
Recombinant soluble, multimeri ...... nza virus infection in ferrets
@ast
Recombinant soluble, multimeri ...... nza virus infection in ferrets
@en
P2093
P2860
P50
P356
P1433
P1476
Recombinant soluble, multimeri ...... nza virus infection in ferrets
@en
P2093
Cornelis A M de Haan
Geert van Amerongen
Joost H C M Kreijtz
Robert P de Vries
Willem Bartelink
P2860
P304
10366-10374
P356
10.1128/JVI.01035-10
P577
2010-08-04T00:00:00Z